RLAY RSI Chart
Last 7 days
-2.0%
Last 30 days
-28.1%
Last 90 days
-30.7%
Trailing 12 Months
-48.1%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2023 | 21.6M | 34.5M | 47.4M | 45.2M |
2022 | 2.0M | 2.1M | 5.5M | 8.8M |
2021 | 62.2M | 41.7M | 21.3M | 830.0K |
2020 | 0 | 7.2M | 5.3M | 82.7M |
2019 | 0 | 0 | 0 | 0 |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Jan 29, 2024 | catinazzo thomas | sold | -19,328 | 9.64 | -2,005 | chief financial officer |
Jan 29, 2024 | bergstrom donald a | sold | -30,635 | 9.64 | -3,178 | president, r&d |
Jan 29, 2024 | adams brian | sold | -18,595 | 9.64 | -1,929 | chief legal officer |
Jan 29, 2024 | rahmer peter | sold | -15,915 | 9.64 | -1,651 | see remarks |
Jan 16, 2024 | catinazzo thomas | acquired | - | - | 200,000 | chief financial officer |
Jan 16, 2024 | rahmer peter | acquired | - | - | 200,000 | see remarks |
Jan 16, 2024 | bergstrom donald a | acquired | - | - | 300,000 | president, r&d |
Jan 16, 2024 | patel sanjiv | acquired | - | - | 762,360 | president and ceo |
Jan 16, 2024 | adams brian | acquired | - | - | 200,000 | chief legal officer |
Dec 27, 2023 | catinazzo thomas | sold | -3,383 | 11.51 | -294 | chief financial officer |
Which funds bought or sold RLAY recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
Mar 22, 2024 | PNC FINANCIAL SERVICES GROUP, INC. | new | - | 506 | 506 | -% |
Mar 21, 2024 | HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | sold off | -100 | -824,180 | - | -% |
Mar 11, 2024 | VANGUARD GROUP INC | added | 0.93 | 28,515,400 | 117,261,000 | -% |
Mar 04, 2024 | CONGRESS ASSET MANAGEMENT CO /MA | added | 0.37 | 386,674 | 1,618,180 | 0.01% |
Mar 01, 2024 | GOLDMAN SACHS GROUP INC | added | 120 | 14,155,800 | 21,654,200 | -% |
Feb 28, 2024 | AMERICAN INTERNATIONAL GROUP, INC. | reduced | -0.4 | 115,156 | 494,085 | -% |
Feb 26, 2024 | PERCEPTIVE ADVISORS LLC | sold off | -100 | -16,341,400 | - | -% |
Feb 16, 2024 | PUBLIC EMPLOYEES RETIREMENT SYSTEM OF OHIO | new | - | 1,083,530 | 1,083,530 | -% |
Feb 16, 2024 | GSA CAPITAL PARTNERS LLP | reduced | -80.44 | -702,000 | 241,000 | 0.02% |
Feb 16, 2024 | PRICE T ROWE ASSOCIATES INC /MD/ | reduced | -0.32 | 22,077,000 | 94,480,000 | 0.01% |
Unveiling Relay Therapeutics Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Relay Therapeutics Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 40.7B | 6.8B | -8.64 | 5.95 | ||||
HILS | 22.4B | 152.6K | -2.4K | 146.8K | ||||
ALNY | 18.8B | 1.8B | -42.76 | 10.3 | ||||
BMRN | 16.5B | 2.4B | 98.3 | 6.81 | ||||
INCY | 12.8B | 3.7B | 21.4 | 3.46 | ||||
MID-CAP | ||||||||
APLS | 7.1B | 396.6M | -13.41 | 17.87 | ||||
BBIO | 5.4B | - | -8.32 | 60.35 | ||||
AXSM | 3.8B | 270.6M | -15.8 | 13.97 | ||||
ARWR | 3.5B | 240.7M | -11.94 | 14.72 | ||||
ACAD | 3.0B | 726.4M | -49.71 | 4.19 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 398.2M | 26.31 | 4.72 | ||||
NVAX | 669.0M | 983.7M | -1.23 | 0.68 | ||||
CRBP | 411.7M | 881.7K | -9.23 | 466.16 | ||||
INO | 324.4M | 4.9M | -2.4 | 66.66 | ||||
IBIO | 14.1M | 2.1M | -0.52 | 2.14 |
Relay Therapeutics Inc News
Income Statement (Quarterly) | |||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q3 | 2019Q2 |
Revenue | -78.2% | 5.00 | 25.00 | 8.00 | 7.00 | 8.00 | 4.00 | 1.00 | 1.00 | 0.00 | 0.00 | 1.00 | 40.00 | 80.00 | 1.00 | 1.00 | 2.00 | 2.00 | 2.00 |
Operating Expenses | -6.7% | 92.00 | 99.00 | 106 | 101 | 73.00 | 86.00 | 78.00 | 63.00 | 68.00 | 62.00 | 194 | 43.00 | 48.00 | 37.00 | 28.00 | 26.00 | 22.00 | 20.00 |
S&GA Expenses | -9.3% | 17.00 | 18.00 | 20.00 | 20.00 | 16.00 | 16.00 | 17.00 | 16.00 | 16.00 | 15.00 | 14.00 | 13.00 | 16.00 | 12.00 | 6.00 | 5.00 | 4.00 | 4.00 |
R&D Expenses | - | - | - | - | - | - | - | - | - | - | - | - | 31.00 | 32.00 | 24.00 | 22.00 | 22.00 | 18.00 | 16.00 |
Net Income | -27.0% | -83.49 | -65.73 | -98.50 | -94.24 | -67.50 | -84.17 | -76.79 | -62.05 | -67.46 | -60.83 | -193 | -42.18 | 35.00 | -36.08 | -26.72 | -24.89 | -19.67 | -17.54 |
Net Income Margin | -9.9% | -7.57* | -6.88* | -22.81* | -37.77* | -126.42* | -64.39* | -61.78* | -92.18* | -120.13* | -11.39* | -5.52* | -1.11* | - | - | - | - | - | - |
Free Cashflow | -17.5% | -89.31 | -75.99 | -70.10 | -69.04 | -59.39 | -68.24 | -58.95 | -51.97 | -40.59 | -54.93 | -28.52 | 46.00 | - | - | - | - | - | - |
Balance Sheet | |||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2019Q4 |
Assets | -6.9% | 844 | 907 | 962 | 1,038 | 1,100 | 1,169 | 889 | 950 | 1,008 | 672 | 714 | 771 | 800 | 752 | 348 | 393 |
Current Assets | -7.4% | 770 | 832 | 884 | 958 | 1,020 | 1,087 | 856 | 916 | 976 | 639 | 681 | 742 | 770 | 722 | 316 | 361 |
Cash Equivalents | -5.0% | 144 | 151 | 146 | 161 | 152 | 355 | 108 | 119 | 283 | 229 | 260 | 263 | 449 | 559 | 137 | 43.00 |
Net PPE | 1.9% | 11.00 | 11.00 | 12.00 | 12.00 | 12.00 | 11.00 | 9.00 | 9.00 | 7.00 | 6.00 | 7.00 | 6.00 | 6.00 | 7.00 | 7.00 | 8.00 |
Liabilities | -28.5% | 92.00 | 129 | 152 | 154 | 150 | 169 | 110 | 108 | 111 | 101 | 96.00 | 39.00 | 37.00 | 38.00 | 36.00 | 36.00 |
Current Liabilities | -40.4% | 30.00 | 51.00 | 72.00 | 70.00 | 64.00 | 71.00 | 44.00 | 42.00 | 24.00 | 29.00 | 25.00 | 16.00 | 14.00 | 16.00 | 13.00 | 12.00 |
Shareholder's Equity | -3.4% | 752 | 778 | 810 | 883 | 950 | 1,000 | 780 | 842 | 898 | 571 | 619 | 733 | 763 | 714 | - | - |
Retained Earnings | -6.3% | -1,400 | -1,317 | -1,251 | -1,152 | -1,058 | -991 | -906 | -830 | -768 | -700 | -639 | -446 | -404 | -439 | -241 | -189 |
Additional Paid-In Capital | 2.6% | 2,153 | 2,099 | 2,067 | 2,042 | 2,019 | 2,004 | 1,698 | 1,681 | 1,667 | 1,272 | 1,258 | 1,179 | 1,167 | 1,153 | 15.00 | 9.00 |
Shares Outstanding | 3.5% | 127 | 123 | 122 | 121 | 121 | 111 | 109 | 108 | 95.00 | 93.00 | 92.00 | 90.00 | - | - | - | - |
Float | - | - | - | 1,500 | - | - | - | 1,800 | - | - | - | 2,264 | - | - | - | - | - |
Cashflow (Quarterly) | ||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 |
Cashflow From Operations | -18.3% | -89,188 | -75,397 | -68,601 | -67,130 | -57,079 | -66,145 | -57,093 | -49,173 | -39,707 | -53,199 | -28,140 | 46,640 | -35,272 | -24,039 | -20,844 | -22,334 | - | - | - |
Share Based Compensation | -11.8% | 19,267 | 21,835 | 23,411 | 21,518 | 13,817 | 13,719 | 15,147 | 13,455 | 10,218 | 12,418 | 16,147 | 9,671 | 14,544 | 11,929 | 4,032 | 1,455 | - | 1,248 | 1,086 |
Cashflow From Investing | -16.4% | 59,678 | 71,365 | 51,277 | 75,314 | -146,936 | 27,187 | 43,388 | -112,384 | -292,745 | 20,787 | 26,068 | -233,621 | -76,420 | 20,073 | 87,648 | 50,371 | - | - | - |
Cashflow From Financing | 131.7% | 21,918 | 9,458 | 2,080 | 1,297 | 1,166 | 285,865 | 1,996 | 883 | 384,012 | 902 | 1,121 | 2,055 | 56.00 | 426,195 | -93.00 | 351 | - | - | - |
Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands | 12 Months Ended | ||
---|---|---|---|
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Revenue: | |||
License and other revenue | $ 25,546 | $ 1,381 | $ 3,029 |
Revenue from Contract with Customer, Product and Service [Extensible Enumeration] | us-gaap:LicenseAndServiceMember | us-gaap:LicenseAndServiceMember | us-gaap:LicenseAndServiceMember |
Total revenue | $ 25,546 | $ 1,381 | $ 3,029 |
Operating expenses: | |||
Research and development expenses | 330,018 | 246,355 | 172,650 |
In-process research and development expenses | 123,000 | ||
Loss on initial consolidation of variable interest entity | 11,855 | ||
Change in fair value of contingent consideration liability | (6,422) | (11,677) | 2,836 |
General and administrative expenses | 74,950 | 65,978 | 57,386 |
Total operating expenses | 398,546 | 300,656 | 367,727 |
Loss from operations | (373,000) | (299,275) | (364,698) |
Other income: | |||
Interest income | 31,045 | 8,786 | 830 |
Other expense | (18) | (20) | (4) |
Total other income, net | 31,027 | 8,766 | 826 |
Net loss | $ (341,973) | $ (290,509) | $ (363,872) |
Net loss per share, basic | $ (2.79) | $ (2.59) | $ (3.82) |
Net loss per share, diluted | $ (2.79) | $ (2.59) | $ (3.82) |
Weighted average shares of common stock, basic | 122,576,527 | 112,233,649 | 95,136,719 |
Weighted average shares of common stock, diluted | 122,576,527 | 112,233,649 | 95,136,719 |
Other comprehensive loss: | |||
Unrealized holding gain (loss) | $ 10,224 | $ (9,332) | $ (1,152) |
Total other comprehensive gain (loss) | 10,224 | (9,332) | (1,152) |
Total comprehensive loss | $ (331,749) | $ (299,841) | $ (365,024) |
Consolidated Balance Sheets - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 143,736 | $ 151,794 |
Investments | 606,350 | 847,123 |
Accounts receivable | 306 | |
Contract asset | 4,913 | |
Prepaid expenses | 16,702 | 12,110 |
Other current assets | 3,315 | 3,259 |
Total current assets | 770,103 | 1,019,505 |
Property and equipment, net | 10,901 | 11,634 |
Operating lease assets | 57,969 | 63,754 |
Restricted cash | 2,707 | 2,578 |
Intangible asset | 2,300 | 2,300 |
Total assets | 843,980 | 1,099,771 |
Current liabilities: | ||
Accounts payable | 9,211 | 10,578 |
Accrued expenses | 14,890 | 22,703 |
Operating lease liabilities | 4,964 | 4,276 |
Other current liabilities | 1,204 | 26,152 |
Total current liabilities | 30,269 | 63,709 |
Operating lease liabilities, net of current portion | 48,502 | 53,466 |
Contingent consideration liability | 13,206 | 32,378 |
Total liabilities | 91,977 | 149,553 |
Commitments and contingencies (Note 12) | ||
Stockholders' equity: | ||
Common stock, $0.001 par value; 300,000,000 shares authorized as of December 31, 2023, and December 31, 2022;127,462,409 and 121,112,234 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively | 127 | 121 |
Additional paid-in capital | 2,152,654 | 2,019,126 |
Accumulated other comprehensive loss | (196) | (10,420) |
Accumulated deficit | (1,400,582) | (1,058,609) |
Total stockholders' equity | 752,003 | 950,218 |
Total liabilities and stockholders' equity | $ 843,980 | $ 1,099,771 |